ClinicalTrials.gg
CompletedNCT05429073Updated Aug 27, 2025Results posted

A Study of RGLS8429 in Healthy Volunteers

A Phase 1 interventional study of RGLS8429 and Placebo volume-matching RGLS8429 dose in Healthy Volunteers, sponsored by Regulus Therapeutics Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-27.

Sponsored by Regulus Therapeutics Inc. (part of Novartis) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States — 14 open to participants now, 25 under way, 1 of them phase 3. Polycystic Kidney, Autosomal Dominant · United States.

Enrollment
38th of 63
32 · median 48
Started
2022
with 5 others
Phase 1
10 of 85
2 open now
Registered
66th of 85
by date
Lead sponsor
3 of 85
Regulus Therapeutics Inc.

Among the 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States, this one is the 38th largest by enrollment of the 63 interventional ones that give a count, is one of 6 that started in 2022, is one of 10 in phase 1, and was the 66th registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

14 of the 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States, or all of them as a file.
02

Study summary

Primary Objective

  • To assess the safety and tolerability of single ascending doses of RGLS8429

Secondary Objectives

  • To identify dose-limiting toxicity (DLT) and to determine the maximum tolerated dose (MTD) of a single SC dose of RGLS8429
  • To characterize the pharmacokinetic (PK) properties of RGLS8429
Read the detailed description

In this randomized, double-blind, placebo-controlled Phase 1 study, a single ascending dose of RGLS8429 or placebo will be administered via subcutaneous (SC) injection to healthy volunteers to evaluate the safety, tolerability, and PK of RGLS8429.

03

Conditions studied

  • Healthy Volunteers

Keywords

  • RGLS8429
  • Autosomal Dominant Polycystic Kidney Disease
  • ADPKD
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, 18 to 55 years of age
  2. (BMI) 18 to 35 kg/m2
  3. Medically healthy, with no medical history in the opinion of the Investigator
  4. Estimated (eGFR) ≥ 90 mL/min/1.73 m2
  5. Must understand and consent to the study procedures explained in the form (ICF) and be willing and able to comply with the protocol

Exclusion criteria

Exclusion Criteria:

  1. Subject is mentally incapacitated or has significant emotional problems
  2. Any medical condition or social circumstance that, in the opinion of the Investigator, may make the subject unlikely to complete the study or comply with study procedures and requirements, or may pose a risk to the subject's safety
  3. History or presence of alcoholism or drug abuse within the past 2 years prior to Screening
  4. Participation in another clinical trial and/or exposure to any drug or approved therapy for investigational use within 28 days or 5 half-lives of the investigational drug's dosing, whichever is longer, prior to dosing. The 28-day and 5-half-life windows will be calculated from the date of the last dosing in the previous study to Day 1 of the current study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    RGLS8429, first dose level

    Eligible participants will receive subcutaneous injection of the first dose level RGLS8429 or placebo

    Drug: RGLS8429 · Drug: Placebo volume-matching RGLS8429 dose

  • Experimental
    RGLS8429, second dose level

    Eligible participants will receive subcutaneous injection of the second dose level RGLS8429 or placebo

    Drug: RGLS8429 · Drug: Placebo volume-matching RGLS8429 dose

  • Experimental
    RGLS8429, third dose level

    Eligible participants will receive subcutaneous injection of the third dose level RGLS8429 or placebo

    Drug: RGLS8429 · Drug: Placebo volume-matching RGLS8429 dose

  • Experimental
    RGLS8429, fourth dose level

    Eligible participants will receive subcutaneous injection of the fourth dose level RGLS8429 or placebo

    Drug: RGLS8429 · Drug: Placebo volume-matching RGLS8429 dose

Interventions

  • DrugRGLS8429

    solution for subcutaneous injection

  • DrugPlacebo volume-matching RGLS8429 dose

    solution for subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs)

    Incidence and severity of adverse events after administration of RGLS8429

    Time frame: Baseline to Day 29

Secondary outcomes

  1. Incidence of DLT and Determination of MTD

    Identify dose limiting toxicity and the maximum tolerated dose after RGLS8429 administration

    Time frame: Baseline to Day 29

  2. Plasma Half-life (T1/2) of RGLS8429

    Measure plasma elimination half-life after RGLS8429 administration

    Time frame: Baseline to Day 15

  3. Plasma Clearance of RGLS8429

    Measure plasma clearance after RGLS8429 administration

    Time frame: Baseline to Day 15

  4. Area Under the Plasma Concentration vs Time Curve (AUC) of RGLS8429

    Measure area under the plasma concentration vs time curve after RGLS8429 administration

    Time frame: Baseline to Day 15

  5. Amount of RGLS8429 Excreted in Urine

    Measure the amount of RGLS8429 excreted in urine after RGLS8429 administration

    Time frame: Baseline to 24-hour

07

Results

Posted Aug 27, 2025

Participant flow

Participant flow — Overall Study
MilestoneRGLS8429, First Dose LevelRGLS8429, Second Dose LevelRGLS8429, Third Dose LevelRGLS8429, Fourth Dose LevelMatching Placebo
Started66668
Completed66668
Not completed00000

Outcome measures

PrimaryIncidence of Adverse Events (AEs)

Incidence and severity of adverse events after administration of RGLS8429

Time frame:
Baseline to Day 29
Reported as:
Number · participants
Incidence of Adverse Events (AEs)
participantsRGLS8429, First Dose LevelRGLS8429, Second Dose LevelRGLS8429, Third Dose LevelRGLS8429, Fourth Dose LevelMatching Placebo
Number of subjects with Grade 3, 4 or 5 treatment-emergent adverse events00000
Number of subjects with Treatment-emergent adverse events leading to discontinuation00000
Number of Subjects with Serious Adverse Events or deaths00000
Number of subjects with at least one treatment-emergent adverse event11313
SecondaryIncidence of DLT and Determination of MTD

Identify dose limiting toxicity and the maximum tolerated dose after RGLS8429 administration

Time frame:
Baseline to Day 29

Results for this outcome have not been posted.

SecondaryPlasma Half-life (T1/2) of RGLS8429

Measure plasma elimination half-life after RGLS8429 administration

Time frame:
Baseline to Day 15

Results for this outcome have not been posted.

SecondaryPlasma Clearance of RGLS8429

Measure plasma clearance after RGLS8429 administration

Time frame:
Baseline to Day 15

Results for this outcome have not been posted.

SecondaryArea Under the Plasma Concentration vs Time Curve (AUC) of RGLS8429

Measure area under the plasma concentration vs time curve after RGLS8429 administration

Time frame:
Baseline to Day 15

Results for this outcome have not been posted.

SecondaryAmount of RGLS8429 Excreted in Urine

Measure the amount of RGLS8429 excreted in urine after RGLS8429 administration

Time frame:
Baseline to 24-hour

Results for this outcome have not been posted.

Adverse events

Collected over All Adverse Events were collecting beginning with the start of study drug administration until the Day 29 End of Study Visit.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RGLS8429, First Dose Level0/6 (0%)0/6 (0%)1/6 (16.7%)
RGLS8429, Second Dose Level0/6 (0%)0/6 (0%)1/6 (16.7%)
RGLS8429, Third Dose Level0/6 (0%)0/6 (0%)3/6 (50%)
RGLS8429, Fourth Dose Level0/6 (0%)0/6 (0%)1/6 (16.7%)
Matching Placebo0/8 (0%)0/8 (0%)3/8 (37.5%)
Most frequent other events
Most frequent other events
EventRGLS8429, First Dose LevelRGLS8429, Second Dose LevelRGLS8429, Third Dose LevelRGLS8429, Fourth Dose LevelMatching Placebo
HeadacheNervous system disorders0/61/61/60/62/8
Eustachian tube dysfunctionEar and labyrinth disorders0/60/61/60/60/8
Gastroesophageal reflux diseaseGastrointestinal disorders0/60/61/60/60/8
Medical device site reactionGeneral disorders0/60/61/60/60/8
SinusitisInfections and infestations1/60/60/60/60/8
Skin abrasionInjury, poisoning and procedural complications0/61/60/60/60/8
Alanine aminotransferase increasedInvestigations0/60/60/61/60/8
EcchymosisSkin and subcutaneous tissue disorders0/61/60/60/60/8
Dry mouthGastrointestinal disorders0/60/60/60/61/8

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)RGLS8429, First Dose LevelRGLS8429, Second Dose LevelRGLS8429, Third Dose LevelRGLS8429, Fourth Dose LevelMatching PlaceboTotal
<=18 years000000
Between 18 and 65 years6666832
>=65 years000000
Age, Continuous
Age, Continuous(Years)RGLS8429, First Dose LevelRGLS8429, Second Dose LevelRGLS8429, Third Dose LevelRGLS8429, Fourth Dose LevelMatching PlaceboTotal
Mean36.3 ± 9.4833.8 ± 6.6834.2 ± 6.1838.2 ± 9.2843.9 ± 6.5837.7 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)RGLS8429, First Dose LevelRGLS8429, Second Dose LevelRGLS8429, Third Dose LevelRGLS8429, Fourth Dose LevelMatching PlaceboTotal
Female3252820
Male3414012
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RGLS8429, First Dose LevelRGLS8429, Second Dose LevelRGLS8429, Third Dose LevelRGLS8429, Fourth Dose LevelMatching PlaceboTotal
Hispanic or Latino6452724
Not Hispanic or Latino021418
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RGLS8429, First Dose LevelRGLS8429, Second Dose LevelRGLS8429, Third Dose LevelRGLS8429, Fourth Dose LevelMatching PlaceboTotal
American Indian or Alaska Native000000
Asian000101
Native Hawaiian or Other Pacific Islander000000
Black or African American022015
White6445726
More than one race000000
Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(participants)RGLS8429, First Dose LevelRGLS8429, Second Dose LevelRGLS8429, Third Dose LevelRGLS8429, Fourth Dose LevelMatching PlaceboTotal
United States6666832
08

Study locations

1 site
  • ICON Early Phase Services
    San Antonio, Texas 78209, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Sep 2022, 2 months.

Results were first posted in Aug 2025, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2022
First posted
Jun 23, 2022
StartActual
Jun 10, 2022
Primary completionActual
Sep 8, 2022
CompletionActual
Sep 8, 2022
Results first posted
Aug 27, 2025
Last update
Aug 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05429073
Responsible party
Sponsor
First posted
Jun 23, 2022
Start date
Jun 10, 2022
Primary completion
Sep 8, 2022
Completion
Sep 8, 2022
Results posted
Aug 27, 2025
Last update
Aug 27, 2025

Study contacts

Rekha Garg, MD
study director · Regulus Therapeutics

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion